Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Cytomegalovirus Infection

Free Subscription Articles published in Clin Transplant Retrieve available abstracts of 26 articles: HTML format

Single Articles

June 2025
1. COPPOLA JA, Shirley DA, Martin E, Probst V, et al
   Use of Letermovir as Secondary Prophylaxis in Cytomegalovirus Resistant Pediatric Heart Transplant Recipients.
   Clin Transplant. 2025;39:e70187.
   PubMed     Abstract available
   
   
   May 2025
2. KLEIBOEKER HL, Descourouez JL, Saddler CM, Al-Adra D, et al
   De Novo Letermovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients.
   Clin Transplant. 2025;39:e70169.
   PubMed     Abstract available
   
   
   April 2025
3. RAO M, Page RL 2nd, Sartain E
   Twelve-Month Clinical and Cost Outcomes of Removal of Cytomegalovirus Intravenous Immune Globulin From Heart Transplantation Protocol.
   Clin Transplant. 2025;39:e70147.
   PubMed     Abstract available
   
   
   January 2025
4. HELDMAN MR, Messina JA, Schlueter AJ, Lee MJ, et al
   Contemporary Cytomegalovirus (CMV) Infections in Low-Risk CMV Seronegative Recipients of Solid Organ Transplants From CMV Seronegative Donors (D-/R-): Time to Reexamine Donor CMV Serostatus.
   Clin Transplant. 2025;39:e70073.
   PubMed     Abstract available
   
   
   December 2024
5. KLEIBOEKER HL, Prom A, Paplaczyk K, Wang J, et al
   Impact of Letermovir for Cytomegalovirus Primary Prophylaxis on Myelosuppression and Immunosuppression in Lung Transplant Recipients.
   Clin Transplant. 2024;38:e70033.
   PubMed     Abstract available
   
   
   November 2024
6. NON LR, Tan CS, Ince D, Razonable RR, et al
   Survey of Post-Prophylaxis Delayed-Onset Cytomegalovirus Management Strategies Among Transplant Providers.
   Clin Transplant. 2024;38:e70015.
   PubMed     Abstract available
   
   
   October 2024
7. BEECHAR VB, Phadke VK, Pouch SM, Mehta AK, et al
   Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
   Clin Transplant. 2024;38:e15480.
   PubMed     Abstract available
   
   
   September 2024
8. MACGOWAN GA, Samuel J, McDiarmid A, Gonzalez-Fernandez O, et al
   Effect of CMV Mismatch on Heart Transplant Outcomes Using a Surveillance and Preemptive Strategy.
   Clin Transplant. 2024;38:e15419.
   PubMed     Abstract available
   
   
   
9. JORGENSON MR, Meyer E, Leverson GE, Descourouez JL, et al
   Cytomegalovirus Post-Prophylaxis Surveillance in High-Risk Kidney and Liver Recipients Prevents CMV End-Organ Disease and Ganciclovir-Resistance.
   Clin Transplant. 2024;38:e15453.
   PubMed     Abstract available
   
   
   June 2024
10. GAN GG, Iyadorai T, Sulaiman NY, Hussein N, et al
    Clinical and Economic Impact of CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation: Perspectives from a Middle-Income Nation.
    Clin Transplant. 2024;38:e15375.
    PubMed     Abstract available
    
    
    May 2024
11. SALTIEL G, Faure E, Assaf A, Chopin MC, et al
    Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
    Clin Transplant. 2024;38:e15327.
    PubMed     Abstract available
    
    
    April 2024
12. RAMPERSAD C, Kong W, Wiebe C, Balshaw R, et al
    Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein-Barr virus, cytomegalovirus, and BK polyomavirus post-kidney transplant: A quality assurance initiative.
    Clin Transplant. 2024;38:e15292.
    PubMed     Abstract available
    
    
    
13. CHIU CY, Mahmood M, Razonable RR, Beam E, et al
    Discordance in serology for cytomegalovirus, Epstein-Barr virus and toxoplasma among thoracic organ donors.
    Clin Transplant. 2024;38:e15301.
    PubMed    
    
    
    
14. CUI J, Zhou Y, Zhao K, Li X, et al
    Application of CMV-IVIg as prophylaxis against cytomegalovirus reactivation in allogeneic hematopoietic stem cell transplantation patients.
    Clin Transplant. 2024;38:e15300.
    PubMed     Abstract available
    
    
    March 2024
15. ROMINE MM, Leeser DB, Kennamer K, Nguyen C, et al
    Early outcomes associated with de novo once-daily extended-release versus twice-daily immediate-release tacrolimus in a predominantly African American kidney transplant population: A single-center observational study.
    Clin Transplant. 2024;38:e15268.
    PubMed     Abstract available
    
    
    
16. ALAM AH, Van Zyl J, Shakoor HI, Farsakh D, et al
    The impact of active cytomegalovirus infection on donor-derived cell-free DNA testing in heart transplant recipients.
    Clin Transplant. 2024;38:e15287.
    PubMed     Abstract available
    
    
    December 2023
17. ZAIS IE, Sirotti A, Iesari S, Campioli E, et al
    Human cytomegalovirus-related gastrointestinal disease after kidney transplantation: A systematic review.
    Clin Transplant. 2023 Dec 8:e15218. doi: 10.1111/ctr.15218.
    PubMed     Abstract available
    
    
    November 2023
18. SINGH P, Von Stein L, McGowan M, Nolan A, et al
    Comparison of outcomes in vaccinated versus unvaccinated COVID-19 kidney transplant recipients, a single center retrospective study-Is the taboo justified?
    Clin Transplant. 2023 Nov 7:e15187. doi: 10.1111/ctr.15187.
    PubMed     Abstract available
    
    
    
19. ZHOU X, Zhang S, Fan J, Zhu X, et al
    Risk factors for BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
    Clin Transplant. 2023;37:e15121.
    PubMed     Abstract available
    
    
    October 2023
20. DIOVERTI MV, Bhaimia E, Yetmar ZA, Melendez DP, et al
    Clinical utility of a cytomegalovirus-specific T cell assay in assessing the risk of post-prophylaxis cytomegalovirus infection and post-treatment relapse.
    Clin Transplant. 2023 Oct 8:e15143. doi: 10.1111/ctr.15143.
    PubMed     Abstract available
    
    
    September 2023
21. JORGENSON MR, Descourouez JL, Saddler CM, Smith JA, et al
    Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
    Clin Transplant. 2023 Sep 27:e15142. doi: 10.1111/ctr.15142.
    PubMed     Abstract available
    
    
    August 2023
22. SERMET K, Goeminne C, Hantz S, Assaf A, et al
    Reliability of QuantiFERON(R)-CMV in predicting CMV recurrence in heart transplant recipients: A single-center retrospective study.
    Clin Transplant. 2023 Aug 29:e15109. doi: 10.1111/ctr.15109.
    PubMed     Abstract available
    
    
    July 2023
23. LERMAN JB, Green CL, Molina MR, Maharaj V, et al
    Multicenter study of universal prophylaxis versus pre-emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation.
    Clin Transplant. 2023 Jul 1:e15065. doi: 10.1111/ctr.15065.
    PubMed     Abstract available
    
    
    May 2023
24. KREISER ML, Dupuis R, Szempruch KR, Chargualaf LM, et al
    Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high-risk abdominal transplant recipients.
    Clin Transplant. 2023 May 31:e15041. doi: 10.1111/ctr.15041.
    PubMed     Abstract available
    
    
    March 2023
25. GARDINER BJ, Bailey JP, Percival MA, Morgan BA, et al
    Incidence and severity of cytomegalovirus infection in seropositive heart transplant recipients.
    Clin Transplant. 2023 Mar 29:e14982. doi: 10.1111/ctr.14982.
    PubMed     Abstract available
    
    
    
26. ZONA E, Jorgenson M, Dolma S, Santos A, et al
    Discordance in cytomegalovirus viremia in kidney recipients from the same donor is associated with the worst outcomes.
    Clin Transplant. 2023 Mar 26:e14979. doi: 10.1111/ctr.14979.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Cytomegalovirus Infection is free of charge.